Heymach Homes in On Emerging Agents in EGFR Exon 20–Mutant NSCLC
John V. Heymach, MD, PhD, discusses the incidence of EGFR exon 20 insertions in lung cancer, diagnostic challenges of identifying EGFR exon 20 insertions, and data from the International Association for the Study of Lung Cancer 2020 World Conference on Lung Cancer with mobocertinib and amivantamab in this patient subset.
Welcome to OncLive On AirTM! I’m your host today, Jessica Hergert.
OncLive On AirTM is a podcast from OncLive, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.
In today’s episode, sponsored by Takeda, we had the pleasure of speaking with John V. Heymach, MD, PhD, chair, professor, and David Bruton, Jr Chair in Cancer Research in the Department of Thoracic/Head and Neck Medical Oncology, and professor in the Department of Cancer Biology, Division of Cancer Medicine at The University of MD Anderson Cancer Center, to discuss EGFR 20 insertion–mutated non–small cell lung cancer (NSCLC).
In our exclusive interview, Heymach discussed the incidence of EGFR exon 20 insertions in lung cancer, diagnostic challenges of identifying EGFR exon 20 insertions, and data from the International Association for the Study of Lung Cancer 2020 World Conference on Lung Cancer with mobocertinib and amivantamab in this patient subset.
